Summary:
- Researchers at McMaster University are investigating the potential of Botulinum neurotoxin type A (BoNT/A), commonly known as Botox, as a novel treatment for major depressive disorder.
- The study explores the "facial feedback hypothesis," suggesting that by inhibiting the facial muscles associated with frowning, the brain receives feedback that modulates emotional states, potentially alleviating depressive symptoms.
- The research aims to provide a biological mechanism for how peripheral muscular interventions can influence central nervous system activity and mood regulation.